P. Drevinek (Praha, Czech Republic), P. Whitaker (Leeds (West Yorkshire), United Kingdom), M. Mall (Berlin, Germany), B. Plant (Cork, Ireland)
Questions of predicting and preventing the progression of pneumofibrosis in children with cystic fibrosis
S. Ilchenko (Dnepr, Ukraine), A. Fialkovska (Dnepr, Ukraine), S. Ivanus (Dnepr, Ukraine)
|  |
Investigation of the CFTR-TGFß1 interaction in inflammatory and fibrotic processes in healthy and CFTR-mutated human bronchial epithelial cells
J. Thomassen (Cologne, Germany), T. Trojan (Cologne, Germany), C. Vohlen (Cologne, Germany), E. Rietschel (Cologne, Germany), S. Van Koningsbruggen-Rietschel (Cologne, Germany), M. Alejandre Alcazar (Cologne, Germany)
| |
Sputum and plasma neutrophil elastase in stable adult patients with cystic fibrosis in relation to chronic Pseudomonas colonization.
A. Abdul Wahab (Doha, Qatar), M. Allangawi (Doha, Qatar), M. Thomas (Doha, Qatar), I. Betahi (Doha, Qatar), S. K Sivaraman (Doha, Qatar), J. Jayakumar (Doha, Qatar), P. Chandra (Doha, Qatar), A. Abou-Samra (Doha, Qatar), M. Ramanjaneya (Doha, Qatar)
|  |
MiRNA expression profile is altered upon cystic fibrosis pulmonary exacerbation
A. Szczepankiewicz (Poznan, Poland), I. Wojsyk-Banaszak (Poznan, Poland), K. Jonczyk-Potoczna (Poznan, Poland), B. Narozna (Poznan, Poland), Z. Stachowiak (Poznan, Poland), Z. Kycler (Poznan, Poland), P. Sobkowiak (Poznan, Poland), A. Breborowicz (Poznan, Poland)
| |
Characteristics of the composition and level of cell-free DNA and nuclease activity in patients with cystic fibrosis
E. Kondratyeva (Moscow, Russian Federation), Y. Kondakova (Novosibirsk, Russian Federation), S. Kostyuk (Moscow, Russian Federation), M. Kon'Kova (Moscow, Russian Federation), E. Ershova (Moscow, Russian Federation), A. Voronkova (Moscow, Russian Federation), V. Sherman (Moscow, Russian Federation), R. Budzinskiy (Moscow, Russian Federation), E. Zhekaite (Moscow, Russian Federation)
| |
The role of antimicrobial peptides in cystic fibrosis in childhood.
E. Kondratyeva (Moscow, Russian Federation), E. Zhekaite (Moscow, Russian Federation), A. Voronkova (Moscow, Russian Federation), V. Sherman (Moscow, Russian Federation), Y. Melyanovskaya (Moscow, Russian Federation), A. Zodbinova (Moscow, Russian Federation)
| |
Evaluation of neutrophils phagocytosis and killing in pulmonary cystic fibrosis patients
E. Mortaz (Tehran, Islamic Republic of Iran), A. Asef (Tehran, Islamic Republic of Iran), E. Azempour (Tehran, Islamic Republic of Iran), H. Ghaffaripour (Tehran, Islamic Republic of Iran), I. Adcock (London, United Kingdom), L. Koenderman (Utrecht, Netherlands)
| |
Clinical correlation of epithelial barrier dysfunction related to neutrophilic inflammation in cystic fibrosis
E. Toprak Kanik (Manisa, Turkey), O. Yilmaz (Manisa, Turkey), E. Ozdogru (Izmir, Turkey), H. Alper (Izmir, Turkey), C. Ulman (Manisa, Turkey), A. Kanik (Izmir, Turkey), Y. Simsek (Manisa, Turkey), H. Yuksel (Manisa, Turkey)
| |
Using sputum proteomics to develop a test for reflux aspiration in cystic fibrosis patients
R. Lord (Manchester, United Kingdom), R. Maher (Liverpool, United Kingdom), V. Harman (Liverpool, United Kingdom), B. Bianco (Manchester, United Kingdom), P. Mcnamara (Liverpool, United Kingdom), R. Beynon (Liverpool, United Kingdom), J. Smith (Manchester, United Kingdom), A. Jones (Manchester, United Kingdom)
| |
A proteomics approach for the identification of species-specific immunogenic proteins in the Mycobacterium abscessus complex
M. Steindor (Düsseldorf, Germany), V. Nkwouano (Düsseldorf, Germany), A. Stefanski (Düsseldorf, Germany), K. Stuehler (Düsseldorf, Germany), T. Ioerger (Texas, United States of America), D. Bogumil (Beer-Sheva, Israel), M. Jacobsen (Düsseldorf, Germany), C. Mackenzie (Düsseldorf, Germany), R. Kalscheuer (Düsseldorf, Germany)
| |
Prevalence of airway isolation of Escherichia coli in a paediatric cystic fibrosis population. A retrospective study.
C. De Manuel Gomez (Madrid, Spain), C. Luna-Paredes (Madrid, Spain), M. Albi Rodríguez (Madrid, Spain), Á. Gimeno Díaz De Atauri (Madrid, Spain), E. Salcedo Lobato (Madrid, Spain)
| |
Characterising pseudomonas carriage patterns using molecular typing.
S. Salehian (Cambridge, United Kingdom), D. Mcshane (Cambridge, United Kingdom)
| |
Fungal colonization in cystic fibrosis – correlating variables
J. Cemlyn Jones (Coimbra, Portugal), M. Afonso (Coimbra, Portugal), F. Gamboa (Coimbra, Portugal)
| |
Is aspergillus isolation (without ABPA) associated with a decline in FEV1 in CF?
H. Winterton (Nottingham, United Kingdom), R. Devaney (Nottingham, United Kingdom), C. Kingsnorth (Nottingham, United Kingdom), M. Hurley (Nottingham, United Kingdom), J. Bhatt (Nottingham, United Kingdom), (Nottingham, United Kingdom)
| |
Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations
N. Farahbakhsh (tehran, Islamic Republic of Iran), S. Tabatabaii (tehran, Islamic Republic of Iran), G. Khanbabaee (tehran, Islamic Republic of Iran), S. Sadr (tehran, Islamic Republic of Iran), M. Kazemi Aghdam (tehran, Islamic Republic of Iran)
| |
Efficacy of Thermal and Chemical Methods of Nebulizer Disinfection of CF Pathogens
M. Collins (Hartford, CT, United States of America), J. Harris (Hartford, CT, United States of America), T. Murray (New Haven, CT, United States of America)
| |
Has Palivizumab prophylaxis effect on long time protection cystic fibrosis children from infections?
A. Folino (Torino, Italy), M. Fissore (Novara, Italy), I. Stura (Torino, Italy), F. Del Monte (Torino, Italy), I. Castagno (Novara, Italy), I. Esposito (Torino, Italy), E. Bignamini (Torino, Italy)
| |
Pseudomonas eradication treatment in Europe: Are there still differences between former East and West?
I. Weber (Rostock, Germany), M. Ballmann (Rostock, Germany)
| |